Benzamide protease inhibitors.
Abstract
This application claims a series of compounds of the formula <CHEM> where HET is a heterocyclic group; n is an integer of 0 to 2 and R<1> is hydrogen or lower alkyl.
Term
Term ended
Projected expiry passed 22 May 2009, 17.3 years ago.
- Priority
- Filed
- Published
- Projected expiry
- Today
10 claims: 2 independent, 8 dependent
- 1A compound of the formula or a pharmaceutically acceptable salt thereof, wherein HET is pyrimid-2-yl, dimethylpyrimid-4-yl, thiazol-2-yl, 4-phenylthiazol-2-yl, 4-phenyl-5-carbethoxythiazol-2-yl, 4-biphenylylthiazol-2-yl, pyrazin-2-yl, 6-chloropyrazin-2-yl, quinol-8-yl, 6-methoxyquinol-8-yl, quinol-3-yl, 1,3,4-thiadiazol-2-yl, 3-phenyl-1,2,4-thiadiazol-5-yl, 5-trifluoromethyl-1,3,4-thiadiazol-2-yl, 5-methylisoxazol-3-yl, 5-chloropyrid-2-yl, 4,5-dicyanoimidazol-2-yl, 5-chlorobenzoxazol-2-yl, indazol-5-yl-2-carbethoxyindol-5-yl or a benzimidazol-2-yl of the formula where X is hydrogen or methyl, Y is hydrogen, methyl, benzoyl, nitro, chloro, fluoro, bromo or methoxy and R² is hydrogen, (C₁-C₃)alkyl, phenethyl, phenacyl, N-(C₁-C₃)alkylcarbamylmethyl, N,N-di(C₁-C₃)alkylcarbamylmethyl, N-(C₁-C₃)alkylcarbamyl, (C₁-C₃)alkoxycarbonylmethyl or N-(p-chlorobenzyl)carbamylmethyl;n is an integer of 0 to 2;and R¹ is hydrogen or (C₁-C₃)alkyl. 1. A process for preparing a compound of the formula wherein HET is pyrimid-2-yl, dimethylpyrimid-4-yl, thiazol-2-yl, 4-phenylthiazol-2-yl, 4-phenyl-5-carbethoxythiazol-2-yl, 4-biphenylylthiazol-2-yl, pyrazin-2-yl, 6-chloropyrazin-2-yl, quinol-8-yl, 6-methoxyquinol-8-yl, quinol-3-yl, 1,3,4-thiadiazol-2-yl, 3-phenyl-1,2,4-thiadiazol-5-yl, 5-trifluoromethyl-1,3,4-thiadiazol-2-yl, 5-methylisoxazol-3-yl, 5-chloropyrid-2-yl, 4,5-dicyanoimidazol-2-yl, 5-chlorobenzoxazol-2-yl, indazol-5-yl-2-carbethoxyindol-5-yl or a benzimidazol-2-yl of the formula where X is hydrogen or methyl, Y is hydrogen, methyl, benzoyl, nitro, chloro, fluoro, bromo or methoxy and R² is hydrogen, (C₁-C₃)alkyl, phenethyl, phenacyl, N-(C₁-C₃)alkylcarbamylmethyl, N,N-di(C₁-C₃)alkylcarbamylmethyl, N-(C₁-C₃)alkylcarbamyl, (C₁-C₃)alkoxycarbonylmethyl or N-(p-chlorobenzyl)carbamylmethyl;n is an integer of 0 to 2;and R¹ is hydrogen or (C₁-C₃)alkyl, which comprises acylating a compound of the formula HET-NH₂ with a benzoic acid of the formula wherein the carboxyl group is activated as an acid chloride, mixed anhydride or active ester, in a reaction-inert solvent in the presence of a catalytic amount of hydroquinone at a reaction temperature of 20-180°C. and, optionally, preparing a pharmaceutically acceptable salt of the product.
- 9A compound according to any one of the preceeding claims for use in medicine.
Independent claims2
37 paragraphs in 8 sections, as filed
This invention relates to novel benzamide compounds and, in particular, to a series of N-heterocyclic-4-guanylalkylbenzamide useful as protease inhibitors. These compounds have application as protease inhibitors, in particular as antiplasmin agents.
U.S. Patent 4,563,527 claims a series of amidinonaphthyl esters of furoic, benzofuroic and thiophene carboxylic acids as protease inhibitors. U.S. Patent 4,732,916 claims a series of 4-guanylmethylbenzamide derivatives as antiulcer agents.
It has now been discovered that novel compounds of the formula <chemistry id="chem0001" num="0001"><img file="EP0343894A1_D0001.tif" /></chemistry> or a pharmaceutically acceptable salt thereof wherein HET is pyrimid-2-yl, dimethylpyrimid-4-yl, thiazol-2-yl, 4-phenylthiazol-2-yl, 4-phenyl-5-carbethoxythiazol-2-yl, 4-biphenylylthiazol-2-yl, pyrazin-2-yl, 6-chloropyrazin-2-yl, quinol-8-yl, 6-methoxyquinol-8-yl, quinol-3-yl, 1,3,4-thiadiazol-2-yl, 3-phenyl-1,2,4-thiadiazol-5-yl, 5-trifluoromethyl-1,3,4-thiadiazol-2-yl, 5-methylisoxazol-3-yl, 5-chloropyrid-2-yl, 4,5-dicyanoimidazol-2-yl, 5-chlorobenzoxazol-2-yl, indazol-5-yl-2-carbethoxyindol-5-yl or a benzimidazol-2-yl of the formula <chemistry id="chem0002" num="0002"><img file="EP0343894A1_D0002.tif" /></chemistry> where X is hydrogen or methyl, Y is hydrogen, methyl, benzoyl, nitro, chloro, fluoro, bromo or methoxy and R² is hydrogen, (C₁-C₃)alkyl, phenethyl, phenacyl, N-(C₁-C₃)alkylcarbamylmethyl, N,N-di(C₁-C₃)alkylcarbamylmethyl, N-(C₁-C₃)alkylcarbamyl, (C₁-C₃)alkoxycarbonylmethyl or N-(<u style="single">p</u>-chlorobenzyl)carbamylmethyl; <u style="single">n</u> is an integer of 0 to 2; and R¹ is hydrogen or (C₁-C₃)alkyl are protease inhibitors, having particular application as inhibitors of serine protease and useful as anti-plasmin and anti-thrombin agents.
A preferred group of compounds are those wherein R¹ is hydrogen and <u style="single">n</u> is 0. Especially preferred within this group are the compound where HET is pyrazin-2-yl, pyrimid-2-yl, 1,3,4-thiadiazol-2-yl, quinol-8-yl, thiazol-2-yl or indazol-5-yl.
A second group of preferred compounds are those where HET is a benzimidazol-2-yl of the formula <chemistry id="chem0003" num="0003"><img file="EP0343894A1_D0003.tif" /></chemistry> where X is hydrogen. Especially preferred within this group are the compounds where Y and R² are each hydrogen, where Y is 5-nitro and R² is hydrogen, where Y is 5-chloro and R² is hydrogen; or where Y is hydrogen and R² is N,N-diethylcarbamylmethyl.
As used herein, the term (C₁-C₃)alkyl defines alkyl having one to three carbon atoms; similar terms can be used to define alkoxy, etc.
Also considered within the scope of the present invention are compounds of the formulae <chemistry id="chem0004" num="0004"><img file="EP0343894A1_D0004.tif" /></chemistry> where HET, <u style="single">n</u> and R¹ are as herein defined.
The compounds of the present invention are prepared by the acylation of the appropriate aminohetercyclic with a carboxy activated benzoic acid derivative.
The activated acid can consist of an acid halide or an activated ester or mixed anhydride. The preferred acylating agent is either the N-hydroxysuccinimide ester or the acid chloride.
The coupling reaction can be achieved by contacting one mole of the appropriate benzoic carboxylic acid N-hydroxysuccinimide ester with from 1 to 2 moles of the requisite aminoheterocyclic and about .01 mole of hydroquinone in a reaction-inert solvent such as dimethylformamide, dimethylsulfoxide, or N-methyl-2-pyrrolidone. The reaction is heated in the dark for about 1 to 36 hours at a reaction temperature of 20-180°C.
On completion of the reaction, the reaction mixture is diluted with methanol, filtered, if necessary, and the filtrate applied to the protonated form of an ionexchange resin (pH 5-6) such as GC 50 (Aldrich Chemical Co., Inc.). The resin-product complex is then loaded on a column and washed sufficiently with methanol, water, dimethylsulfoxide, dimethylformamide or acetonitrile or mixtures thereof, to remove all the remaining, unreacted aminoheterocyclic.
The product is freed from the resin complex by eluting the column with a 0.1-0.01 molar solution of an acid such as hydrochloric acid, hydrobromic acid, methane sulfonic acid, lactic acid or acetic acid in such solvents as water, methanol or acetonitrile. The wash liquids are combined and concentrated. The product, isolated as the salt of the acid wash, precipitates as the solution is concentrated, and is collected by filtration. Further purification can be carried out by recrystallization from such solvents as dimethylformamide, tetrahydrofuran, ethyl acetate, chloroform, dimethylsulfoxide, N-methyl-2-pyrrolidone, diethyl ether or methanol or mixtures thereof.
A modification of this procedure comprises contacting one mole of the 4-guanidinobenzoic acid derivative as an acid addition salt with the silating agent bis-trimethylsilylacetamide, followed by formation of the acid chloride using thionyl chloride. The acid chloride is then treated in tetrahydrofuran with as much as a two-fold excess of the appropriate aminohetercyclic, or a one fold excess plus an excess of an acid scavenger, such as triethylamine.
After a reaction time of about 30 minutes, at ambient temperatures, the reaction is diluted with sufficient water to precipitate the product, which is recrystallized as previously described.
Compounds of the present invention wherein HET is <chemistry id="chem0005" num="0005"><img file="EP0343894A1_D0005.tif" /></chemistry> are converted to compounds where HET is <chemistry id="chem0006" num="0006"><img file="EP0343894A1_D0006.tif" /></chemistry> where R² is as defined, but other than hydrogen.
Acylation of the benzimidazole nitrogen with isocyanates is carried out in a reaction-inert solvent such as dimethylformamide, dimethylsulfoxide, N-methyl-2-pyrrolidone. The reaction can be conducted at from about room temperature to 100°C. Reaction time is about 24 hours and ambient temperatures and 30 minutes to a few hours at elevated temperatures.
When reacting the isocyanate with the compounds identified, it is necessary to use the acid addition salt of the guanidinobenzamide reactant to prevent interaction of the guanyl portion with the isocyanate. Further, it is preferred to use an excess of isocyanate to aid in the completion of the reaction, a ratio of one mole of benzimidazole derivative per five moles of isocyanate provides the desired product.
The reaction mixture, at the end of the reaction period, is diluted with diethyl ether and the precipitated product filtered and purified.
Alkylation of the benzimidazole nitrogen is carried out between one mole of compound containing the benzimidazole moiety and about 5-6 moles of alkylating agent. In addition, the alkylation makes use of from 1 to 4 equivalents of base per mole of starting reagent. Such bases include alkali metal alkoxides and carbonates. The solvent, reaction times and temperature are about the same for the alkylation reaction as for the corresponding acylation reaction.
As previously indicated, the present invention embraces pharmaceutically acceptable salts of the biologically active compounds. Such salts are those which are non-toxic at the dosages administered. Pharmaceutically acceptable acid addition salts include e.g., the hydrochloride, hydrobromide, hydroiodide, sulfate, bisulfate, phosphate, acid phosphate, acetate, lactate, maleate, mesylate, fumarate, citrate, acid citrate, tartrate, bitartrate, succinate, gluconate and saccharate salts. Conventional methods of forming acid addition salts may be employed.
Plasmin, a serine protease enzyme existinginf the blood, is the result of the action of plasminogen activator on the proenzyme plasminogen. Plasmin plays an important role in capillary blood flow and in the dissolution of fibrin. However, when this enzyme is present in abnormal amounts it causes hemorrhagic diseases. In such cases, the use of an anti-plasmin agent is extremely important. The compounds of the present possess this anti-plasmin activity, which can be readily demonstrated by the assay of H. Zimmerman, <u style="single">et al</u>., <u style="single">Proc. Natl. Acad. Sci.</u>, <u style="single">75</u>, 750 (1978).
The compounds of the present invention can be administered as anti-plasmin agents by either the oral or parental routes of administration, with the former being preferred for reasons of patient convenience and comfort. In general, these anti-plasmin compounds are normally administered orally in dosages ranging from about 6 mg to about 400 mg per kg of body weight per day and 1 mg to about 200 mg per kg of body weight per day when given parenterally; variations will necessarily occur depending upon the condition of the subject being treated and the particular compound being administered. It is to be noted that these compounds may be administered in combination with pharmaceutically acceptable carriers by either of the routes previously indicated, and that such administration can be carried out in both single and multiple dosages.
The novel compounds of the invention can be orally administered in a wide variety of different dosage forms, i.e., they may be formulated with various pharmaceutically acceptable inert carriers in the form of tablets, capsules, lozenges, troches, hard candies, powders, sprays, aqueous suspensions, elixirs, syrups, and the like. Such carriers include solid diluents or fillers, sterile aqueous media and various non-toxic organic solvents, etc. Moreover, such oral pharmaceutical formulations can be suitably sweetened and/or flavored by means of various agents of the type commonly employed for such purposes. In general, the compounds of this invention are present in such oral dosage forms at concentration levels ranging from about 0.5% to about 90% by weight of the total composition, in amounts which are sufficient to provide the desired unit dosages.
For purposes of oral administration, tablets containing various excipients such as sodium citrate, calcium carbonate and calcium phosphate may be employed along with various disintegrants such as starch and preferably potato and tapioca starch, alginic acid and certain complex silicates, together with binding agents such as polyvinylpyrrolidone, sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often very useful for tabletting purposes. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules; preferred materials in this connection would also include lactose or milk sugar as well as high molecular weight polyethylene glycols. When aqueous suspensions and/or elixirs are desired of oral administration, the essential active ingredient therein may be combined with various sweetening or flavoring agents, coloring matter or dyes and, if so desired, emulsifying and/or suspending agents as well, together with such diluents as water, ethanol, propylene glycol, glycerin and various like combinations thereof.
The following examples illustrate the invention but are not to be contrued as limiting the same.
EXAMPLE 1
4-Guanidino-N-(pyrazin-2-yl)benzamide hydrochloride n = 0; R¹ = H; and HET = 2-pyrazinyl)
A solution of 1.84 g. (19.2 m. mol) of 2-aminopyrazine, 3.0 g. (9.6 m. mol) of 4-guanidinobenzoic acid N-hydroxysuccinimide ester and 300 mg. of hydroquinone in 25 ml. of N-methyl-2-pyrrolidone was heated in the dark under an inert atmosphere at 170°C for 7 hours. The cooled reaction mixture was diluted with 300 ml. of methanol and 3 ml. of pyridine and treated with 50 g. of CG50 ion exchange resin (H+ form). The solution was decanted and treated with an additional 25 g. of resin. The solution was again decanted and treated with 25 g. of resin. The resin fractions were loaded on a column such that the last resin fraction was loaded first, the first, last. The column was eluted with 2 l. of methanol and then with .02 <u style="single">N</u> hydrochloric acid in methanol. The fractions containing the product were combined and concentrated <u style="single">in vacuo</u> to a solid. The residue was dissolved in methanol and precipitated with diethyl ether. The product was filtered, washed with <u style="single">i</u>-propanol and dried, 232 mg., m.p. 278-280°C.
EXAMPLE 2
Using the procedure of Example 1, except where noted, and starting with the appropriate reagents, the following compounds were prepared as the hydrochloride salt: <chemistry id="chem0007" num="0007"><img file="EP0343894A1_D0007.tif" /></chemistry><tables id="tabl0001" num="0001"><table frame="all"><tgroup cols="6" colsep="1" rowsep="0"><colspec colnum="1" colname="col1" colwidth="26.25mm" /><colspec colnum="2" colname="col2" colwidth="26.25mm" /><colspec colnum="3" colname="col3" colwidth="26.25mm" /><colspec colnum="4" colname="col4" colwidth="26.25mm" /><colspec colnum="5" colname="col5" colwidth="26.25mm" /><colspec colnum="6" colname="col6" colwidth="26.25mm" /><thead valign="top"><row rowsep="1"><entry namest="col1" nameend="col1" align="center">HET</entry><entry namest="col2" nameend="col2" align="center">n</entry><entry namest="col3" nameend="col3" align="center">REACTION TIME</entry><entry namest="col4" nameend="col4" align="center">REACTION TEMP. °C</entry><entry namest="col5" nameend="col5" align="center">HYDROQUINONE</entry><entry namest="col6" nameend="col6" align="center">m.p. °C</entry></row></thead><tbody valign="top"><row><entry namest="col1" nameend="col1" align="left">benzimidazol-2-yl</entry><entry namest="col2" nameend="col2" align="right">0</entry><entry namest="col3" nameend="col3" align="right">7 hrs</entry><entry namest="col4" nameend="col4" align="right">170</entry><entry namest="col5" nameend="col5" align="right">+</entry><entry namest="col6" nameend="col6" align="right">265-266</entry></row><row><entry namest="col1" nameend="col1" align="left">5-NO₂-benzimidazol-2-yl</entry><entry namest="col2" nameend="col2" align="right">0</entry><entry namest="col3" nameend="col3" align="right">7 hrs</entry><entry namest="col4" nameend="col4" align="right">170</entry><entry namest="col5" nameend="col5" align="right">+</entry><entry namest="col6" nameend="col6" align="right">235-237</entry></row><row><entry namest="col1" nameend="col1" align="left">pyrimidin-2-yl</entry><entry namest="col2" nameend="col2" align="right">0</entry><entry namest="col3" nameend="col3" align="right">72 hrs</entry><entry namest="col4" nameend="col4" align="right">110</entry><entry namest="col5" nameend="col5" align="right">-</entry><entry namest="col6" nameend="col6" align="right">178-180<sup>a</sup></entry></row><row><entry namest="col1" nameend="col1" align="left">6-Cl-pyrazin-2-yl</entry><entry namest="col2" nameend="col2" align="right">0</entry><entry namest="col3" nameend="col3" align="right">72 hrs</entry><entry namest="col4" nameend="col4" align="right">110</entry><entry namest="col5" nameend="col5" align="right">-</entry><entry namest="col6" nameend="col6" align="right">273 dec.</entry></row><row><entry namest="col1" nameend="col1" align="left">2,6-(CH₃)₂-pyrimidin-4-yl</entry><entry namest="col2" nameend="col2" align="right">0</entry><entry namest="col3" nameend="col3" align="right">120 hrs</entry><entry namest="col4" nameend="col4" align="right">110<sup>b</sup></entry><entry namest="col5" nameend="col5" align="right">-</entry><entry namest="col6" nameend="col6" align="right">238 dec.<sup>a</sup></entry></row><row><entry namest="col1" nameend="col1" align="left">4-phenyl-thiazol-2-yl</entry><entry namest="col2" nameend="col2" align="right">0</entry><entry namest="col3" nameend="col3" align="right">5 hrs</entry><entry namest="col4" nameend="col4" align="right">110</entry><entry namest="col5" nameend="col5" align="right">-</entry><entry namest="col6" nameend="col6" align="right">250-252</entry></row><row><entry namest="col1" nameend="col1" align="left">1,3,4-thiadazol-2-yl</entry><entry namest="col2" nameend="col2" align="right">0</entry><entry namest="col3" nameend="col3" align="right">5 min</entry><entry namest="col4" nameend="col4" align="right">170</entry><entry namest="col5" nameend="col5" align="right">-</entry><entry namest="col6" nameend="col6" align="right">318-320</entry></row><row rowsep="1"><entry namest="col1" nameend="col1" align="left">3-phenyl-1,2,4-thiadazol-5-yl</entry><entry namest="col2" nameend="col2" align="right">0</entry><entry namest="col3" nameend="col3" align="right">3 hrs</entry><entry namest="col4" nameend="col4" align="right">170</entry><entry namest="col5" nameend="col5" align="right">-</entry><entry namest="col6" nameend="col6" align="right">308-310<sup>a</sup></entry></row></tbody></tgroup><tgroup cols="6" colsep="0" rowsep="0"><colspec colnum="1" colname="col1" colwidth="26.25mm" /><colspec colnum="2" colname="col2" colwidth="26.25mm" /><colspec colnum="3" colname="col3" colwidth="26.25mm" /><colspec colnum="4" colname="col4" colwidth="26.25mm" /><colspec colnum="5" colname="col5" colwidth="26.25mm" /><colspec colnum="6" colname="col6" colwidth="26.25mm" /><tbody valign="top"><row><entry namest="col1" nameend="col6" align="justify"><sup>a</sup> Purified by column chromatography using chloroform-methanol-acetic acid (18:5:1;V:V:V)</entry></row><row><entry namest="col1" nameend="col6" align="justify"><sup>b</sup> Solvent dimethylformamide</entry></row></tbody></tgroup></table></tables>
EXAMPLE 4
4-Guanidino-N-(quinol-8-yl)benzamide (HET = 8-quinolyl; n = 0; and R¹ = H)
A mixture of 200 mg. (.92 m. mol) 4-guanidinobenzoic acid hydrochloride and 190 mg. (.93 m. mol) of bis-trimethylsilylacetamide in 20 ml. of dry tetrahydrofuran was heated at reflux until a solution was achieved, and then cooled to room temperature. Thionyl chloride (380 mg., 1.86 m. mol) was added and the reaction mixture allowed to stir for 5 min. 8-Aminoquinoline (670 mg., 4.64 m. mol) was added in 5 ml. of tetrahydrofuran and the mixture allowed to stir for 30 min. Water (.2 ml) was added to the reaction mixture and the solids filtered and dissolved in 60 ml. of methanol and 120 ml. of chloroform. Addition of diethyl ether precipitated the desired product, 153 mg., m.p. 271-273°C.
EXAMPLE 5
Employing the procedure of Example 4, except where noted, and starting with the requisite reagents, the following products were prepared: <chemistry id="chem0008" num="0008"><img file="EP0343894A1_D0008.tif" /></chemistry><tables id="tabl0002" num="0002"><table frame="all"><tgroup cols="5" colsep="1" rowsep="0"><colspec colnum="1" colname="col1" colwidth="31.50mm" /><colspec colnum="2" colname="col2" colwidth="31.50mm" /><colspec colnum="3" colname="col3" colwidth="31.50mm" /><colspec colnum="4" colname="col4" colwidth="31.50mm" /><colspec colnum="5" colname="col5" colwidth="31.50mm" /><thead valign="top"><row rowsep="1"><entry namest="col1" nameend="col1" align="center">HET</entry><entry namest="col2" nameend="col2" align="center">EQUIV. AMINE/ACID</entry><entry namest="col3" nameend="col3" align="center">REACTION TIME</entry><entry namest="col4" nameend="col4" align="center">REACTION TEMP. °C</entry><entry namest="col5" nameend="col5" align="center">m.p., °C</entry></row></thead><tbody valign="top"><row><entry namest="col1" nameend="col1" align="left">5-methylisoxazol-3-yl</entry><entry namest="col2" nameend="col2" align="right">6:1</entry><entry namest="col3" nameend="col3" align="right">30 min</entry><entry namest="col4" nameend="col4" align="right">25</entry><entry namest="col5" nameend="col5" align="right">242-244</entry></row><row><entry namest="col1" nameend="col1" align="left">5-chloropyridin-2-yl</entry><entry namest="col2" nameend="col2" align="right">6:1</entry><entry namest="col3" nameend="col3" align="right">16 hrs</entry><entry namest="col4" nameend="col4" align="right">25</entry><entry namest="col5" nameend="col5" align="right">255-260</entry></row><row><entry namest="col1" nameend="col1" align="left">5-trifluromethyl-1,3,4-thiadiazol-2-yl</entry><entry namest="col2" nameend="col2" align="right">7:1</entry><entry namest="col3" nameend="col3" align="right">21 hrs</entry><entry namest="col4" nameend="col4" align="right">25</entry><entry namest="col5" nameend="col5" align="right">326-328</entry></row><row><entry namest="col1" nameend="col1" align="left">4-phenyl-5-carbethoxythiazol-2-yl</entry><entry namest="col2" nameend="col2" align="right">7:1</entry><entry namest="col3" nameend="col3" align="right">24 hrs</entry><entry namest="col4" nameend="col4" align="right">25</entry><entry namest="col5" nameend="col5" align="right">180-185</entry></row><row><entry namest="col1" nameend="col1" align="left">5-(p-nitrophenylsulfonyl)thiazol-2-yl</entry><entry namest="col2" nameend="col2" align="right">5:1</entry><entry namest="col3" nameend="col3" align="right">2 hrs</entry><entry namest="col4" nameend="col4" align="right">100</entry><entry namest="col5" nameend="col5" align="right">285 dec.<sup>a</sup></entry></row><row><entry namest="col1" nameend="col1" align="left">thiazol-2-yl</entry><entry namest="col2" nameend="col2" align="right">5:1</entry><entry namest="col3" nameend="col3" align="right">30 min</entry><entry namest="col4" nameend="col4" align="right">25</entry><entry namest="col5" nameend="col5" align="right">175 dec.</entry></row><row><entry namest="col1" nameend="col1" align="left">4,5-dicyanoimidazol-2-yl</entry><entry namest="col2" nameend="col2" align="right">5:1</entry><entry namest="col3" nameend="col3" align="right">24 hrs<sup>b</sup></entry><entry namest="col4" nameend="col4" align="right">25</entry><entry namest="col5" nameend="col5" align="right">211-215</entry></row><row><entry namest="col1" nameend="col1" align="left">5-chlorobenzoxazol-2-yl</entry><entry namest="col2" nameend="col2" align="right">5:1</entry><entry namest="col3" nameend="col3" align="right">30 min</entry><entry namest="col4" nameend="col4" align="right">25</entry><entry namest="col5" nameend="col5" align="right">205-210</entry></row><row><entry namest="col1" nameend="col1" align="left">4-biphenylylthiazol-2-yl</entry><entry namest="col2" nameend="col2" align="right">5:1</entry><entry namest="col3" nameend="col3" align="right">48 hrs<sup>c</sup></entry><entry namest="col4" nameend="col4" align="right">25</entry><entry namest="col5" nameend="col5" align="right">286-288</entry></row><row><entry namest="col1" nameend="col1" align="left">indazol-5-yl</entry><entry namest="col2" nameend="col2" align="right">5:1</entry><entry namest="col3" nameend="col3" align="right">48 hrs<sup>c</sup></entry><entry namest="col4" nameend="col4" align="right">25</entry><entry namest="col5" nameend="col5" align="right">285 dec.</entry></row><row><entry namest="col1" nameend="col1" align="left">quinolin-3-yl</entry><entry namest="col2" nameend="col2" align="right">6:1</entry><entry namest="col3" nameend="col3" align="right">30 min</entry><entry namest="col4" nameend="col4" align="right">25</entry><entry namest="col5" nameend="col5" align="right">282-285</entry></row><row><entry namest="col1" nameend="col1" align="left">5-benzoylbenzimidazol-2-yl</entry><entry namest="col2" nameend="col2" align="right">5:1</entry><entry namest="col3" nameend="col3" align="right">24 hrs<sup>d</sup></entry><entry namest="col4" nameend="col4" align="right">25</entry><entry namest="col5" nameend="col5" align="right">235-240</entry></row><row><entry namest="col1" nameend="col1" align="left">5,6-dimethylbenzimidazol-2-yl</entry><entry namest="col2" nameend="col2" align="right">5:1</entry><entry namest="col3" nameend="col3" align="right">24 hrs<sup>d</sup></entry><entry namest="col4" nameend="col4" align="right">25</entry><entry namest="col5" nameend="col5" align="right">233-237</entry></row><row rowsep="1"><entry namest="col1" nameend="col1" align="left">2-carbethoxyindol-5-yl</entry><entry namest="col2" nameend="col2" align="right">6:1</entry><entry namest="col3" nameend="col3" align="right">10 min</entry><entry namest="col4" nameend="col4" align="right">25</entry><entry namest="col5" nameend="col5" align="right">210 dec.<sup>a</sup></entry></row></tbody></tgroup><tgroup cols="5" colsep="0" rowsep="0"><colspec colnum="1" colname="col1" colwidth="31.50mm" /><colspec colnum="2" colname="col2" colwidth="31.50mm" /><colspec colnum="3" colname="col3" colwidth="31.50mm" /><colspec colnum="4" colname="col4" colwidth="31.50mm" /><colspec colnum="5" colname="col5" colwidth="31.50mm" /><tbody valign="top"><row><entry namest="col1" nameend="col5" align="justify"><sup>a</sup> Purified by column chromatography using chloroform-methanol-acetic acid (18:5:1;V:V:V).</entry></row><row><entry namest="col1" nameend="col5" align="justify"><sup>b</sup> Solvent N-methyl-2-pyrrolidone-tetrahydrofuran (1:5;V:V).</entry></row><row><entry namest="col1" nameend="col5" align="justify"><sup>c</sup> Solvent N-methyl-2-pyrrolidone-tetrahydrofuran (1:2;V:V).</entry></row><row><entry namest="col1" nameend="col5" align="justify"><sup>d</sup> Solvent N-methyl-2-pyrrolidone-tetrahydrofuran (1:4;V:V).</entry></row></tbody></tgroup></table></tables>
EXAMPLE 6
4-Guanidino-N-(5-chloroimidazol-2-yl)benzamide (HET = 5-chloroimidazol-2-yl; n = 0; and R¹ = H)
A mixture of 970 mg. (4.48 m. mol) of 4-guanidinobenzoic acid and 910 mg. (4.48 m. mol) of bis-trimethylsilylacetamide in dry tetrahydrofuran was heated to reflux for five minutes. After cooling the resulting solution of thionylchloride, 1.07 g. (8.95 m. mol) was added, followed after 20 minutes by the addition of 1.5 g. (8.95 m. mol) of 2-amino-5-chloroimidazole and 1.81 g. (17.9 m. mol) of triethyl amine in 10 ml. of tetrahydrofuran. After 16 hours at room temperature .40 ml. of water was added and the solids filtered, washed with chloroform and recrystallized from methanol-chloroform-diethyl ether, 435 mg., m.p. 263-265°C.
EXAMPLE 7
Employing the procedure of Example 6, and starting with the appropriate reagents, the following compounds were prepared: <chemistry id="chem0009" num="0009"><img file="EP0343894A1_D0009.tif" /></chemistry><tables id="tabl0003" num="0003"><table frame="all"><tgroup cols="6" colsep="1" rowsep="0"><colspec colnum="1" colname="col1" colwidth="26.25mm" /><colspec colnum="2" colname="col2" colwidth="26.25mm" /><colspec colnum="3" colname="col3" colwidth="26.25mm" /><colspec colnum="4" colname="col4" colwidth="26.25mm" /><colspec colnum="5" colname="col5" colwidth="26.25mm" /><colspec colnum="6" colname="col6" colwidth="26.25mm" /><thead valign="top"><row rowsep="1"><entry namest="col1" nameend="col1" align="center">HET</entry><entry namest="col2" nameend="col2" align="center">EQUIV AMINE/ACID</entry><entry namest="col3" nameend="col3" align="center">EQUIV TEA<sup>a</sup>/ACID</entry><entry namest="col4" nameend="col4" align="center">REACTION TIME</entry><entry namest="col5" nameend="col5" align="center">REACTION TEMP. °C</entry><entry namest="col6" nameend="col6" align="center">m.p., °C</entry></row></thead><tbody valign="top"><row><entry namest="col1" nameend="col1" align="left">5-bromobenzimidazol-2-yl</entry><entry namest="col2" nameend="col2" align="right">2</entry><entry namest="col3" nameend="col3" align="right">4</entry><entry namest="col4" nameend="col4" align="right">3 hrs</entry><entry namest="col5" nameend="col5" align="right">25</entry><entry namest="col6" nameend="col6" align="right">265-268</entry></row><row><entry namest="col1" nameend="col1" align="left">1-methylbenzimidazol-2-yl</entry><entry namest="col2" nameend="col2" align="right">2</entry><entry namest="col3" nameend="col3" align="right">4</entry><entry namest="col4" nameend="col4" align="right">48 hrs</entry><entry namest="col5" nameend="col5" align="right">25</entry><entry namest="col6" nameend="col6" align="right">265-270</entry></row><row rowsep="1"><entry namest="col1" nameend="col1" align="left">6-methoxyquinolin-8-yl</entry><entry namest="col2" nameend="col2" align="right">2</entry><entry namest="col3" nameend="col3" align="right">4</entry><entry namest="col4" nameend="col4" align="right">30 min</entry><entry namest="col5" nameend="col5" align="right">25</entry><entry namest="col6" nameend="col6" align="right">280 dec.<sup>b</sup></entry></row></tbody></tgroup><tgroup cols="6" colsep="0" rowsep="0"><colspec colnum="1" colname="col1" colwidth="26.25mm" /><colspec colnum="2" colname="col2" colwidth="26.25mm" /><colspec colnum="3" colname="col3" colwidth="26.25mm" /><colspec colnum="4" colname="col4" colwidth="26.25mm" /><colspec colnum="5" colname="col5" colwidth="26.25mm" /><colspec colnum="6" colname="col6" colwidth="26.25mm" /><tbody valign="top"><row><entry namest="col1" nameend="col6" align="justify"><sup>a</sup> TEA = triethyl amine.</entry></row><row><entry namest="col1" nameend="col6" align="justify"><sup>b</sup> Purified by column chromotograhy using chlorform-methanol-acetic acid (18:5:1;V:V:V).</entry></row></tbody></tgroup></table></tables>
EXAMPLE 8
4-Guanidino-N-(1-N-methylcarbamylbenzimidazol-2-yl)benzamide (n = 0; R¹ = H; and HET = 1-(N-methylcarbamyl)benzimidazol-2-yl)
The product of Example 1 (600 mg., 1.81 m. mol) of 520 mg. (9.07 m. mol) of methylisocyanate were added to 10 ml. of dry N-methyl-2-pyrrolidone and allowed to stir at room temperature for 24 hours. The mixture was poured into 200 ml. of diethyl ether and the resulting precipitate filtered and chromatographed on silica gel using chloroform-methanol-acetic acid (18:5:1;V:V:V) as the eluent. The fractions containing the product were combined, concentrated <u style="single">in vacuo</u> to dryness and the residue triturated with methanol, 76 mg., m.p. 188-190°C.
EXAMPLE 9
Using the procedure of Example 8 and starting with the product of Example 1 and the requisite alkylating agent and base, the following compounds were synthesized: <chemistry id="chem0010" num="0010"><img file="EP0343894A1_D0010.tif" /></chemistry><tables id="tabl0004" num="0004"><img file="EP0343894A1_D0011.tif" /></tables>
Contents8
19 sheets
Sheet 1 Sheet 2 Sheet 3 Sheet 4 Sheet 5 Sheet 6 Sheet 7 Sheet 8 Sheet 9 Sheet 10 Sheet 11 Sheet 12 Sheet 13 Sheet 14 Sheet 15 Sheet 16 Sheet 17 Sheet 18 Sheet 19
Every citation, both ways
| Document | Relation | Office | Cited during |
|---|---|---|---|
| EA019357B1 | Cited by | Eurasian Patent Organization (EAPO) | Search report |
| US6100423A | Cited by | United States of America | Search report |
| US6720344B2 | Cited by | United States of America | Applicant |
| US10363243B2 | Cited by | United States of America | Applicant |
| EP0912549A4 | Cited by | European Patent Office (EPO) | Search report |
| US7858641B2 | Cited by | United States of America | Applicant |
| WO9945027A1 | Cited by | World Intellectual Property Organization (WIPO) | International search |
| US6960582B2 | Cited by | United States of America | Applicant |
| US6028223A | Cited by | United States of America | Search report |
| WO03066597A2 | Cited by | World Intellectual Property Organization (WIPO) | International search |
| US7368453B2 | Cited by | United States of America | Applicant |
| US7625909B2 | Cited by | United States of America | Applicant |
| US6638927B2 | Cited by | United States of America | Applicant |
| US6831199B1 | Cited by | United States of America | Applicant |
| US7138420B2 | Cited by | United States of America | Applicant |
| EP0530524A1 | Cited by | European Patent Office (EPO) | Search report |
| US6995269B2 | Cited by | United States of America | Applicant |
| EP0912549A1 | Cited by | European Patent Office (EPO) | Search report |
| EP0620221A1 | Cited by | European Patent Office (EPO) | Search report |
| US5290943A | Cited by | United States of America | Search report |
| WO2009035788A1 | Cited by | World Intellectual Property Organization (WIPO) | International search |
| AU741295B2 | Cited by | Australia | Search report |
| US6716840B2 | Cited by | United States of America | Applicant |
| US7034033B2 | Cited by | United States of America | Applicant |
| WO2004014905A1 | Cited by | World Intellectual Property Organization (WIPO) | International search |
| US7858631B2 | Cited by | United States of America | Applicant |
| US5453512A | Cited by | United States of America | Search report |
| WO03066597A3 | Cited by | World Intellectual Property Organization (WIPO) | International search |
| US7189727B2 | Cited by | United States of America | Applicant |
| WO2009035788A1 | Cited by | World Intellectual Property Organization (WIPO) | International search |
| EP0001727A2 | Cites | European Patent Office (EPO) | Search report |
| EP0001727A2 | Cites | European Patent Office (EPO) | Search report |
| EP0049071A1 | Cites | European Patent Office (EPO) | Search report |
| EP0049071A1 | Cites | European Patent Office (EPO) | Search report |
| EP0061882A1 | Cites | European Patent Office (EPO) | Search report |
| EP0061882A1 | Cites | European Patent Office (EPO) | Search report |
| EP0196547A1 | Cites | European Patent Office (EPO) | Search report |
| EP0196547A1 | Cites | European Patent Office (EPO) | Search report |
| EP0258095A1 | Cites | European Patent Office (EPO) | Search report |
| EP0258095A1 | Cites | European Patent Office (EPO) | Search report |
| EP0261503A1 | Cites | European Patent Office (EPO) | Search report |
| EP0261503A1 | Cites | European Patent Office (EPO) | Search report |
| GB1122957A | Cites | United Kingdom | Search report |
| GB1122957A | Cites | United Kingdom | Search report |
| GB1400540A | Cites | United Kingdom | Search report |
| GB1400540A | Cites | United Kingdom | Search report |
| GB1551735A | Cites | United Kingdom | Search report |
| GB1551735A | Cites | United Kingdom | Search report |
| FR1557679A | Cites | France | Search report |
| FR1557679A | Cites | France | Search report |
| FR2017676A1 | Cites | France | Search report |
| FR2017676A1 | Cites | France | Search report |
| FR2400516A2 | Cites | France | Search report |
| FR2400516A2 | Cites | France | Search report |
| US2502528A | Cites | United States of America | Search report |
| US2502528A | Cites | United States of America | Search report |
| US3736330A | Cites | United States of America | Search report |
| US3736330A | Cites | United States of America | Search report |
| US4343945A | Cites | United States of America | Search report |
| US4343945A | Cites | United States of America | Search report |
| US4732916A | Cites | United States of America | Search report |
| US4732916A | Cites | United States of America | Search report |
| CH570759A5 | Cites | Switzerland | Search report |
| CH570759A5 | Cites | Switzerland | Search report |
38 members in 19 offices
Priority claims4
| Document | Office | Kind | Date |
|---|---|---|---|
| 197927 | United States of America | – | |
| 19792788 | United States of America | A | |
| 197927 | – | – | – |
| US19880197927 | – | – | – |
Members38
| Document | Office | Kind | |
|---|---|---|---|
| DK249089D0 | Denmark | D0 | |
| FI892497A0 | Finland | A0 | |
| NO892058D0 | Norway | D0 | |
| US4874864A | United States of America | A | |
| IE891668L | Ireland | L | |
| FI892497A | Finland | A | |
| FI892497L | Finland | L | |
| DK249089A | Denmark | A | |
| NO892058L | Norway | L | |
| HUT49860A | Hungary | A | |
| EP0343894A1This record | European Patent Office (EPO) | A1 | |
| AU3509789A | Australia | A | |
| PT90623A | Portugal | A | |
| KR890017237A | Republic of Korea | A | |
| JPH0217177A | Japan | A | |
| NZ229235A | New Zealand | A | |
| US4948891A | United States of America | A | |
| US4948901A | United States of America | A | |
| AU602294B2 | Australia | B2 | |
| HU201314B | Hungary | B | |
| ZA893865B | South Africa | B | |
| KR910004207B1 | Republic of Korea | B1 | |
| EP0343894B1 | European Patent Office (EPO) | B1 | |
| AT77083T | Austria | T | |
| ATE77083T1 | Austria | T1 | |
| DE68901746D1 | Germany | D1 | |
| DE68901746T2 | Germany | T2 | |
| ES2032229T3 | Spain | T3 | |
| IL90336A | Israel | A | |
| GR3005072T3 | Greece | T3 | |
| MY104021A | Malaysia | A | |
| NO173867B | Norway | B | |
| NO173867C | Norway | C | |
| FI91254B | Finland | B | |
| FI91254C | Finland | C | |
| JPH0667905B2 | Japan | B2 | |
| IE61151B1 | Ireland | B1 | |
| PT90623B | Portugal | B |
50 legal events, as 5 offices reported them to INPADOC
Over the term
Point at a mark for the eventEvents
| Event | Code | Office | |
|---|---|---|---|
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Announcement of lapse in spainLapsedFD2A | FD2A | ES | |
| Notification of lapseLapsedST | ST | FR | |
| Se: european patent has lapsedLapsedEUG | EUG | EP | |
| Nl: lapsed or anulled due to non-payment of the annual feeLapsedNLV4 | NLV4 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Gb: european patent ceased through non-payment of renewal feeCeasedGBPC | GBPC | EP | |
| Annulment or lapse due to non-payment of feesLapsed3005072MM2A | MM2A | GR | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Be: lapsedLapsedBERE | BERE | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Se: european patent in force in swedenEAL | EAL | EP | |
| Patent ceasedCeasedPL | PL | CH | |
| Lu: last paid annual feeEPTA | EPTA | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| No opposition filedOpposition26N | 26N | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| No opposition filed within time limitOppositionORIGINAL CODE: 0009261PLBE | PLBE | EP | |
| Information on the status of an ep patent application or granted ep patentGrantedSTATUS: NO OPPOSITION FILED WITHIN TIME LIMITSTAA | STAA | EP | |
| Validation in greece3005072FG4A | FG4A | GR | |
| Definitive protectionFG2A | FG2A | ES | |
| Fr: translation filedET | ET | EP | |
| It: translation for a ep patent filedITF | ITF | EP | |
| It: translation for a ep patent filedITF | ITF | EP | |
| Corresponds to:REF | REF | EP | |
| Designated contracting statesAK | AK | EP | |
| Corresponds to:REF | REF | EP | |
| (expected) grantORIGINAL CODE: 0009210GRAA | GRAA | EP | |
| First examination report despatched17Q | 17Q | EP | |
| Request for examination filed17P | 17P | EP | |
| Designated contracting statesAK | AK | EP | |
| Public reference made under article 153(3) epc to a published international application that has entered the european phaseORIGINAL CODE: 0009012PUAI | PUAI | EP |
Numbers
- Publication
- 0343894
- Publication, DOCDB
- 0343894
- Publication, EPODOC
- EP0343894
- Application
- 89305142
- Application, DOCDB
- 89305142
- Application, EPODOC
- EP19890305142
Titles6
- German
- Benzamide Protease-Inhibitoren
- English
- Benzamide protease inhibitors
- French
- Inhibiteurs benzamidiques de protéase
- German
- Benzamide Protease-Inhibitoren.
- English
- Benzamide protease inhibitors.
- French
- Inhibiteurs benzamidiques de protéase.
Classification
- CPC, 17
- C07D285/135
- A61P3/00
- C07D209/40
- A61P7/04
- C07D213/75
- A61P43/00
- C07D215/40
- C07D231/56
- C07D233/90
- C07D235/30
- C07D239/42
- C07D241/20
- C07D261/14
- C07D263/58
- C07D277/46
- C07D277/54
- C07D285/08
- IPC, 34
- C07D209 34
- A61K31 41
- A61K31 415
- A61K31 4184
- A61K31 42
- A61K31 423
- A61K31 425
- A61K31 426
- A61K31 433
- A61K31 47
- A61K31 495
- A61K31 496
- A61K31 505
- A61P3 00
- A61P7 04
- A61P43 00
- C07D209 40
- C07D209 42
- C07D213 75
- C07D215 38
- C07D215 40
- C07D231 56
- C07D233 90
- C07D235 30
- C07D239 42
- C07D241 20
- C07D261 14
- C07D263 58
- C07D277 20
- C07D277 46
- C07D277 54
- C07D285 08
- C07D285 12
- C07D285 135
Designated states13
- Contracting states, 13
- Austria
- Belgium
- Switzerland
- Germany
- Spain
- France
- United Kingdom
- Greece
- Italy
- Liechtenstein
- Luxembourg
- Netherlands (Kingdom of the)
- Sweden